Group 1 - The core point of the article highlights the significant improvement in the confidence and entrepreneurial spirit of private enterprises in China, particularly in the healthcare sector, following the recent private enterprise symposium [2][3] - As of March 2025, there are over 57 million registered private enterprises in China, accounting for 92.3% of the total, with a year-on-year increase of 7.1% in new private enterprises in Q1 [2] - The private healthcare sector, which has faced a prolonged "winter" period post-pandemic, is now seeing renewed hope and potential for recovery [3][5] Group 2 - The private healthcare sector has experienced significant challenges, with over 2,000 private hospitals going bankrupt from 2020 to 2024, and a 94% increase in bankruptcies in 2024 compared to 2023 [4][5] - The difficulties faced by private healthcare institutions stem from policy changes, such as the DRG/DIP payment reform, which has adversely affected their financial viability [6] - Many private healthcare institutions expanded rapidly during better economic times, leading to high costs and debt levels, which have now become unsustainable [7] Group 3 - Despite the challenges, there are still opportunities for private healthcare institutions, particularly in areas like AI and digital health, which can enhance service delivery and patient management [10][12] - The recent symposium emphasized the importance of embracing technology and innovation, with leaders in the industry advocating for a collaborative relationship between public and private healthcare sectors [14][15] - The sentiment expressed by industry leaders suggests that the current economic environment, while challenging, also presents a unique opportunity for capable enterprises to differentiate themselves and thrive [15]

近期三博脑科（301293）发布2025年一季报，证券之星财报模型分析如下： 三博脑科的销售费用、管理费用和财务费用总计达到了4801.18万元，占营业收入的比例为12.2%，较去 年同期增长了20.34%。费用的快速增长可能会对公司未来的盈利能力产生影响。 四、资产负债状况 值得注意的是，公司的货币资金从2024年一季度末的11.47亿元减少至2025年一季度末的6.16亿元，降幅 达46.26%。与此同时，有息负债大幅增加至2.66亿元，同比增长400.13%。此外，应收账款也出现了显 著增长，从7426.7万元增至1.16亿元，增幅为56.84%，应收账款与利润的比例高达110.9%，需引起重 视。 五、每股指标 三博脑科2025年一季度财务表现：收入增长但多项指标承压 一、营业收入与利润 三博脑科在2025年第一季度实现了3.93亿元的营业总收入，同比增长16.78%。归母净利润达到3831.36 万元，同比增长14.56%；扣非净利润为3860.63万元，同比增长19.4%。这表明公司在报告期内保持了一 定的增长势头。 二、毛利率与净利率 尽管收入有所增长，但公司的毛利率和净利率表现却不尽如人意。2 ...

| 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 泰康人寿保险有限责任公司-分红-个人分红-019L-FH002深 | 119.37 | 0.74 | 退出 | 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1900 | 0.1600 | 18.75 | 0.2100 | | 每股净资产（元） | 11.34 | 14.9 | -23.89 | 10.33 | | 每股公积金(元) | 7.92 | 10.69 | -25.91 | 5.77 | | 每股未分配利润(元) | 2.80 | 3.15 | -11.11 | 3.50 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.93 | 3.37 | 16.62 | 3.12 | | 净利润(亿元) | 0.38 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥393,473,847.68, representing a 16.78% increase compared to ¥336,930,401.64 in the same period last year[5] - Net profit attributable to shareholders was ¥38,313,576.61, up 14.56% from ¥33,444,602.02 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 19.40% to ¥38,606,346.69 from ¥32,333,153.81 in the previous year[5] - Basic and diluted earnings per share were both ¥0.19, an increase of 18.75% compared to ¥0.16 in the previous year[5] - Total operating revenue for the current period reached ¥393,473,847.68, an increase of 16.7% compared to ¥336,930,401.64 in the previous period[18] - Net profit for the current period was ¥41,055,460.56, representing a growth of 5.3% from ¥38,749,465.53 in the previous period[19] - The net profit attributable to the parent company was ¥38,313,576.61, an increase of 14.0% compared to ¥33,444,602.02 in the previous period[19] - Basic earnings per share for the current period was ¥0.19, up from ¥0.16 in the previous period[19] Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 99.52%, dropping to ¥136,584.64 from ¥28,472,761.60 in the same period last year[5] - The company's cash and cash equivalents decreased from 708,348,100.12 CNY to 616,263,821.89 CNY, a decline of approximately 13.00%[15] - The total current assets decreased from 980,464,070.04 CNY to 887,378,992.30 CNY, a decline of approximately 9.46%[15] - The company's fixed assets decreased slightly from 606,595,212.30 CNY to 605,101,855.98 CNY[15] - Operating cash flow net amount was 136,584.64, a significant decrease from 28,472,761.60 in the previous period[22] - Cash inflow from operating activities totaled 404,525,922.79, compared to 375,826,914.79 last year, reflecting an increase of approximately 7.5%[22] - Cash outflow from operating activities was 404,389,338.15, up from 347,354,153.19, indicating a rise of about 16.4%[22] - The net increase in cash and cash equivalents was -92,084,278.23, contrasting with an increase of 324,686,913.70 in the previous period[23] - The ending balance of cash and cash equivalents was 468,314,039.97, down from 1,146,809,266.74 last year[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 37,673[10] - TBP 3Doctors (HK) Limited holds 15.70% of shares, totaling 32,330,025 shares[10] - Zhang Yang, a domestic individual, holds 10.59% of shares, totaling 21,815,703 shares[10] - The total number of restricted shares at the end of the period is 45,041,295 shares, with no changes during the reporting period[12] - The company has a significant shareholder structure with Zhang Yang, Yu Chunjiang, Shi Xiangen, and Luan Guoming acting as concerted actors, collectively controlling the company[11] - The company has no preferred shareholders or changes in preferred shareholder structure during the reporting period[11] Liabilities and Equity - Total assets at the end of the reporting period were ¥3,589,563,529.09, reflecting a 1.65% increase from ¥3,531,288,628.12 at the end of the previous year[5] - Total liabilities increased to ¥918,604,788.64, compared to ¥901,385,348.22 in the previous period[17] - Shareholders' equity attributable to the parent company increased by 1.67% to ¥2,336,754,598.79 from ¥2,298,441,022.18 at the end of the previous year[5] - The total equity attributable to the parent company was ¥2,336,754,598.79, an increase from ¥2,298,441,022.18 in the previous period[17] Operational Changes - The contribution to revenue growth was primarily due to the consolidation of Dahuang Guoze into the group on November 30, 2024[9] - The decrease in net cash flow from operating activities was attributed to changes in medical insurance prepayment and increased cash payments for goods and services[9] - The company received government subsidies amounting to ¥399,818.20, which were closely related to its normal business operations[7] - Long-term borrowings increased to ¥196,604,871.23, compared to ¥135,775,842.49 in the previous period, indicating a strategic move towards leveraging for growth[18] - The company established Sanbo Brain Science (Beijing) Health Industry Technology Co., Ltd. with a registered capital of 100 million CNY, holding a 100% stake[13] Accounting and Reporting - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[24] - The first quarter report was not audited, indicating a potential area for further scrutiny[24]

中新网北京4月23日电(赵方园)脑机接口明星概念股三博脑科董事长突遭立案调查。 4月22日，三博脑科发布公告称，公司收到内蒙古自治区监察委员会签发的关于公司控股股东、实际控 制人之一暨董事长张阳的《留置通知书》和《立案通知书》。 4月23日，三博脑科在投资者互动平台回答称，经公司初步了解，本事项为个人原因导致，与公司无 关。 公开资料显示，三博脑科董事长张阳现年60岁，高级工商管理专业，硕士研究生学历。 1988年至1992年，张阳曾在北京照相机总厂、北京海淀北科仪器厂工作；1992年至2004年，任北京市北 科数字医疗技术有限公司董事长、总经理；2004年至2025年3月，任三博脑科总经理；2014年至今，任 三博脑科董事长。 目前其旗下共运营8家医院，分布在全国6个省级行政区，分别位于北京、重庆、昆明、福建、成都和河 南，开放床位数2200余张；2024年门诊量90余万人次，住院患者超7万人次，神经外科专科手术超6000 台。在此次对张阳实施留置的内蒙古自治区，三博脑科并未运营医院。 根据三博脑科近日发布的2024年财报，去年公司实现营业收入14.29亿元，同比增长8.84%；实现归母净 利润1.05亿元 ...

Group 1: Economic Performance in Guangdong - In the first quarter of 2025, Guangdong's GDP reached 33,525.51 billion yuan, with a year-on-year growth of 4.1%, an increase of 0.6 percentage points compared to the previous year [1] - The primary industry added value was 934.45 billion yuan, growing by 3.3%; the secondary industry added value was 12,002.53 billion yuan, growing by 3.7%; and the tertiary industry added value was 20,588.53 billion yuan, growing by 4.3% [1] - The service sector emerged as the main growth engine, indicating a robust economic recovery [1] Group 2: Trade Performance in Shenzhen - In March 2025, Shenzhen's total import and export value reached 3,870.5 billion yuan, with a year-on-year growth of 12.3%, outpacing the national growth rate by 6.3 percentage points [2] - Exports amounted to 2,185.3 billion yuan, growing by 8.8%, while imports were 1,685.2 billion yuan, growing by 17.2% [2] - The strong performance in trade reflects Shenzhen's internal growth momentum and resilience against risks [2] Group 3: Employment Situation in Hong Kong - The unemployment rate in Hong Kong for the first quarter of 2025 was 3.2%, unchanged from the previous period, with an underemployment rate of 1.1% [3] - Total employment reached 3.6927 million, a decrease of approximately 16,800 from the previous period, while the total labor force decreased by about 5,800 to 3.8155 million [3] - Economic growth in mainland China and government stimulus measures are expected to support labor demand despite external uncertainties [3] Group 4: Financial Support for SMEs in Macau - The Macau government launched a loan interest subsidy plan for small and medium-sized enterprises (SMEs), effective from April 22, 2025, to April 22, 2026 [4] - Eligible SMEs can apply for interest subsidies on loans up to 5 million Macau patacas, with a maximum subsidy period of three years and an interest rate cap of 4% [4] - This initiative aims to reduce financing costs and alleviate cash flow pressures for SMEs, supporting their stable operations [4] Group 5: Stock Market Performance - On April 22, 2025, the Shenzhen Component Index closed at 9,870.05 points, down by 0.36% [5] - Notable gainers included Meichen Technology, with a price of 1.66 yuan and a rise of 20.29%, and Xincheng Technology, with a price of 16.66 yuan and a rise of 20.03% [6] - Significant decliners included *ST Jiyuan, with a price of 0.24 yuan and a drop of 20.00% [6]

以下文章来源于每日经济新闻 ，作者每经记者 每日经济新闻 . 中国主流财经全媒体。互联网新闻信息服务许可证编号：51120190017 。 来源：每日经济新闻 4月21日，三博脑科（SZ301293）发布公告，称公司收到了关于控股股东、实际控制人之一、董事长张阳个人的《留置通知书》和《立案通知书》。 公告显示，上述两份通知书由内蒙古自治区监察委员会签发，公司已对相关工作进行了妥善安排，日常生产经营不会受到重大影响。《每日经济新闻》记 者注意到，根据公告，4月16日，张阳曾主持三博脑科第三届董事会第十二次会议。 实际上，几天前这家国内规模最大的神经专科医院集团刚发布了一份不错的年报。年报显示，公司2024年实现营业收入14.29亿元，同比增长8.84%；实现 归母净利润1.05亿元，同比增长34.24%。2025年1月30日，张阳在接受媒体采访时还表示，三博脑科将从医疗服务向医疗健康科技转变。 01 从业时间超过30年持股市值超9亿元，去年年薪172万元 公开资料显示，张阳，男，1965年10月出生，高级工商管理专业，硕士研究生学历。张阳在医疗行业的从业时间超过三十年，最早的履历是1992年到2004 年，在北 ...

作 者丨闫硕 编 辑丨季媛媛 图 源丨图虫 4月2 1日晚间，三博脑科发布公告称，公司现收到内蒙古自治区监察委员会签发关于公司控股 股东、实际控制人之一暨董事长张阳个人的《留置通知书》和《立案通知书》。消息一经发 出，引起业内广泛关注。 三博脑科是以神经专科为特色的医疗服务集团，于2 0 0 3年由神经医学专家栾国明、于春江、 石祥恩及资深医疗管理专家张阳等人创建。2 0 2 3年5月，三博脑科正式在深交所上市。目前其 旗下共运营8家医院，分布在全国6个省级行政区，开放床位数2 2 0 0余张；2 0 2 4年门诊量9 0余 万人次，住院患者超7万人次，神经外科专科手术超6 0 0 0台。 根据三博脑科近日发布的2 0 2 4年财报，去年公司实现营业收入1 4 . 2 9亿元，同比增长8 . 8 4%； 实现归母净利润1 . 0 5亿元，同比增长3 4 . 2 4%。 事实上，作为脑机接口概念的明星股，业内普遍关注三博脑科的最新动态。有观点认 为，三博脑科高管的突然变动无疑给市场带来了不确定性。投资者对公司的未来表现 或将产生疑虑。当前，三博脑科面临着公司治理、战略长期推进以及技术落地等多重 考验。 二级市场 ...

21世纪经济报道记者 闫硕 北京报道 4月21日晚间，三博脑科发布公告称，公司现收到内蒙古自治区监察委员会签发关于公司控股股东、实 际控制人之一暨董事长张阳个人的《留置通知书》和《立案通知书》。消息一经发出，引起业内广泛关 注。 三博脑科是以神经专科为特色的医疗服务集团，于2003年由神经医学专家栾国明、于春江、石祥恩及资 深医疗管理专家张阳等人创建。2023年5月，三博脑科正式在深交所上市。目前其旗下共运营8家医院， 分布在全国6个省级行政区，开放床位数2200余张；2024年门诊量90余万人次，住院患者超7万人次，神 经外科专科手术超6000台。 根据三博脑科近日发布的2024年财报，去年公司实现营业收入14.29亿元，同比增长8.84%；实现归母净 利润1.05亿元，同比增长34.24%。 事实上，作为脑机接口概念的明星股，业内普遍关注三博脑科的最新动态。有观点认为，三博脑科高管 的突然变动无疑给市场带来了不确定性。投资者对公司的未来表现或将产生疑虑。当前，三博脑科面临 着公司治理、战略长期推进以及技术落地等多重考验。 二级市场上，4月22日，三博脑科跳空低开；截至收盘，报40.44元/股，下跌超10% ...

三博是指博医、博教、博研。三博脑科创始人和实控人为张阳、栾国明、于春江、石祥恩。后三人均为 知名神经医学专家，主要教育和执业单位包括首都医科大学、北京天坛医院、北京医院等。张阳无医学 履历，主要承担医疗管理工作。 张阳出生于1965年10月，毕业于北京理工大学。他的主要任职经历包括，1988年至1992年，曾在北京照 相机总厂、北京海淀北科仪器厂工作；1992年至2004年，任北京市北科数字医疗技术有限公司董事长、 总经理；2004年至2014年，任三博脑科总经理；2014年起，任三博脑科董事长兼总经理。同时，张阳担 任中国非公立医疗机构协会副会长、中国医院协会民营医院管理分会副会长、北京市非公立医疗机构协 会终身名誉会长。 4月21日，民营医疗服务上市公司三博脑科（301293.SZ）披露，公司控股股东、实际控制人之一暨董事 长张阳被内蒙古自治区监察委员会留置和立案。 4月22日，三博脑科股价一度下跌超12%。《中国经营报》记者电话咨询三博脑科证券事务部。相关人 士表示，截至目前，公司没有在内蒙古的业务，公司的医院都在其他省份，暂不了解具体原因，该事件 以相关机关后续披露的调查结果为准。 记者查询三博脑科2 ...